National Comprehensive Cancer Network

Presenters

Moderator: Clifford Goodman, PhD
The Lewin Group

Peter B. Bach, MD, MAPP
Memorial Sloan-Kettering Cancer Center

Joseph S. Bailes, MD
American Society of Clinical Oncology

Schumarry H. Chao, MD, MBA
SHC & Associates, Inc.

Peter Juhn, MD, MPH
Johnson & Johnson

Lee Newcomer, MD, MHA
UnitedHealthcare

Deborah Schrag, MD, MPH
Memorial Sloan-Kettering Cancer Center

Jayson S. Slotnik, JD, MPH
Biotechnology Industry Organization

Mary Lou Smith, JD, MBA
Research Advocacy Network

Margaret A. Tempero, MD
UCSF Comprehensive Cancer Center

Sean Tunis, MD, MSc
Rubix Health

Faculty Disclosure Statements

All faculty participating in NCCN continuing education activities are expected to disclose any conflict(s) of interest related to the content of their presentation(s) as defined by the ACCME’s and ANCC’s Standards for Commercial Support.

The speakers listed below have disclosed that they have no financial interests, arrangements, or affiliations with the manufacturer of any products or devices to be discussed in this activity or who may financially support the activity:

Peter B. Bach, MD, MAPP
Joseph S. Bailes, MD
Peter Juhn, MD, MPH
Deborah Schrag, MD, MPH
Jayson S. Slotnik, JD, MPH

The speakers listed below have disclosed that they have financial interests, arrangements, or affiliations with the manufacturer of any products or devices to be discussed in this activity or who may financially support the activity:

Schumarry H. Chao, MD, MBA
Consultant:  Abbott Laboratories; Boehringer Ingelheim GmbH; Daiichi- Sankyo Co., Ltd.; Genzyme Corporation; Johnson & Johnson; Novartis Pharmaceuticals Corporation; sanofi-aventis U.S.

Clifford Goodman, PhD
Speaker:  Alcon, Inc.; Eli Lilly and Company; Guidant Corporation; Roswell Park Cancer Institute  (All honoraria were paid to The Lewin Group)

Lee Newcomer, MD, MHA
Employee:  UnitedHealthcare
Board Member:  Nicollet Health Systems

Mary Lou Smith, JD, MBA
Speaker:  Eli Lilly and Company
Grant Support:  AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Genentech,Inc.; GHI Medicare

Margaret A. Tempero, MD
Consultant:  Eli Lilly and Company; ImClone Systems Incoporated; Pfizer Inc.; sanofi-aventis U.S.

Sean Tunis, MD, MSc
Speaker:  Johnson & Johnson
Consultant:  Amgen Inc.; AnorMED Inc.; AstraZeneca Pharmaceuticals LP; Biogen Idec.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Predictive Biosciences, Inc.; Veridex, LLC

All speakers have indicated that their presentations will not include discussion of investigational or unlabeled uses of commercial products.

Program Overview

Our nation's biomedical research enterprise is delivering a broad array of innovative and promising drugs, biologics, devices, and procedures.  While these technologies bode well for improved effectiveness and quality in cancer care, the introduction of these technologies also portends significant increases in the cost of managing patients with cancer.  The NCCN Roundtable: Cancer Care – Cost, Access, and Value will discuss the ability of our country to offer availability and access to new advances while absorbing the increased costs associated with them.  Thought leaders from interested constituencies will provide their perspectives on this issue that is so important to those living with cancer.

Educational Objectives

Following this activity, participants should be able to:

• Compare and contrast the advantages and difficulties for cancer care created by technological advances in the treatment of patients
• Describe the perspectives of various stakeholders (payers, physicians, patients, etc.) toward the cost, access, and value of cancer care

Intended Audience

This educational activity is designed to meet the needs of physicians, nurses, and other clinical professionals who manage patients with cancer.

Activity Instructions

Continuing education credit will be awarded to participants who listen to the presentation and complete the evaluation.  Participants should review the learning objectives and faculty disclosure statement prior to listening to a presentation in its entirety.  You must be connected to the Internet in order to review and complete the evaluation form.  A statement of credit will be electronically generated once you complete the evaluation form.  To receive credit, this activity must be completed no later than August 29, 2008.  There is no fee for participating in this activity.

Download Podcast

Listen to MP3

Podcast Evaluation

Accreditation Information

Physicians

The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

NCCN designates this educational activity for a maximum of 1.25 AMA PRA Category
1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses

This activity is approved for 1.2 contact hours.  National Comprehensive Cancer Network is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation or PA Nurses approval or endorsement of any product.

Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.

Release date:  July 10, 2007
Expiration date:  July 10, 2008